Company Encyclopedia
View More
name
Well Pharmaceutical
603351.SH
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China. It is involved in the bio-based material manufacturing, sales, and technology development; technical development and consulting; bio-based material technology research and development; biochemical product technology research and development; food and food additive production and sales; and research and development of new material technologies, as well as provides technical services; and manufactures and sells electronic materials. The company also exports its products to Europe, the United States, Southeast Asia, and internationally.
3.137 T
603351.SHMarket value -Rank by Market Cap -/-

Financial Score

11/12/2025 Update
C
Commodity ChemicalsIndustry
Industry Ranking190/271
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.61%B
    • Profit Margin11.23%B
    • Gross Margin30.27%C
  • Growth ScoreC
    • Revenue YoY-0.97%D
    • Net Profit YoY0.52%C
    • Total Assets YoY13.43%B
    • Net Assets YoY5.39%B
  • Cash ScoreC
    • Cash Flow Margin890.73%B
    • OCF YoY-0.97%D
  • Operating ScoreC
    • Turnover0.54C
  • Debt ScoreB
    • Gearing Ratio31.69%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Well Pharmaceutical: Shareholder Tang Qunsong pledged 3.15 million shares

    Well Pharmaceutical announced that major shareholder Tang Qunsong has pledged 3.15 million shares. The pledge start date is August 19, 2025, and the pledge expiration date is August 18, 2027. The pledgee is China Galaxy Securities Co., Ltd. This pledge accounts for 22.32% of Tang Qunsong's holdings and 2.33% of the company's total share capital. As of the announcement date, Tang Qunsong has cumulatively pledged 9.6 million shares, accounting for 68.03% of his holdings and 7.09% of the company's total share capital

    Zhitong·
    SH
    603351
    -0.34%
    Zhitong·
    SH
    603351
    -0.34%

    Well Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 72.7669 million yuan, a year-on-year decrease of 7.77%

    Well Pharmaceutical released its semi-annual report for 2025, with operating revenue of 674 million yuan, a year-on-year decrease of 2.10%; net profit attributable to the parent company was 72.7669 million yuan, a year-on-year decrease of 7.77%. The net profit after deducting non-recurring gains and losses was 72.2489 million yuan, a year-on-year increase of 4.12%. Basic earnings per share were 0.54 yuan

    Zhitong·
    SH
    603351
    -0.34%
    Zhitong·
    SH
    603351
    -0.34%

    Well Pharmaceutical: Shareholders Chen Xinguo, Tang Qunsong, and Shun Taizonghua conduct share pledges and releases

    Well Pharmaceutical announced that shareholders Chen Xinguo, Tang Qunsong, and Nanjing Shuntai Zonghua have conducted share pledges and releases. Chen Xinguo pledged 4.5 million shares, accounting for 31.89% of his holdings and 3.32% of the company's total share capital; Tang Qunsong pledged 3.85 million shares, accounting for 27.28% of his holdings and 2.84% of the company's total share capital; Shuntai Zonghua pledged 3.7 million shares, accounting for 36.48% of his holdings and 2.73% of the company's total share capital. At the same time, Chen Xinguo and Tang Qunsong released 5.35 million shares and 4.8 million shares, accounting for 3.95% and 3.54% of the company's total share capital, respectively

    Zhitong·
    SH
    603351
    -0.34%
    Zhitong·
    SH
    603351
    -0.34%

    Well Pharmaceutical: Shuntai Zonghua plans to reduce its holdings by no more than 1% of shares

    Well Pharmaceutical announced that Shuntai Zonghua plans to reduce its holdings by no more than 1.3544 million shares through centralized bidding transactions between August 20 and November 17, 2025, accounting for approximately 1% of the company's total share capital. This reduction does not include the shares held indirectly by the controlling shareholder and actual controllers Wu Renrong, Gao Zhengsong, and Chen Xinguo in Shuntai Zonghua

    Zhitong·
    SH
    603351
    -0.34%
    Zhitong·
    SH
    603351
    -0.34%

    The biopharmaceutical sector continued to rise in the afternoon, with FUSHILAI hitting the daily limit

    The biopharmaceutical sector continued to rise in the afternoon, with FUSHILAI, Xizang Weixinkang Pharmaceutical, and Well Pharmaceutical hitting the daily limit, while Salubris, Hengrui Pharma, and Dongcheng Biochem had the largest gains

    Zhitong·
    SH
    600276
    +0.03%
    SZ
    002675
    -3.26%
    SH
    603676
    -1.91%
    Zhitong·
    SH
    600276
    +0.03%
    SZ
    002675
    -3.26%
    SH
    603676
    -1.91%
    © 2025 Longbridge｜Disclaimer